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ABSTRACT
Long noncoding RNAs (lncRNAs) are transcribed by genomic regions (exceeding
200 nucleotides in length) that do not encode proteins. While the exquisite regulation
of lncRNA transcription can provide signals of malignant transformation, lncRNAs
control pleiotropic cancer phenotypes through interactions with other cellular
molecules including DNA, protein, and RNA. Recent studies have demonstrated that
dysregulation of lncRNAs is influential in proliferation, angiogenesis, metastasis,
invasion, apoptosis, stemness, and genome instability in colorectal cancer (CRC), with
consequent clinical implications. In this review, we explicate the roles of different
lncRNAs in CRC, and the potential implications for their clinical application.

are restricted to specific cell types to a greater degree
than mRNA [3]. They frequently have evolutionarily
conserved function, secondary structure, and regions
of microhomology, despite minimal overall sequence
similarity [4]. However, the functions of the vast majority
of these transcripts remain unknown. Evidence supports
the important role lncRNAs perform in CRC (Figure 1),
via incompletely understood mechanisms. In this review,
we comprehensively detail the functional roles of
lncRNAs in maintaining the hallmarks of malignancy in
colorectal cancer, and their potential clinical applications
in the treatment of CRC (Table 1).

INTRODUCTION
Colorectal cancer is a frequently diagnosed and
fatal malignancy worldwide, with nearly 1.4 million
newly diagnosed cases in 2012 [1]. The conventional
chemotherapeutic strategies for CRC involve the use of
highly toxic drugs, which cause undesirable side-effects
[2]. It is therefore important to identify both novel
biomarkers and therapies for early diagnosis and improved
treatment.
Recently, the genomics has identified unexpected
non-protein coding regions of the genome. The list of
long noncoding RNAs (lncRNAs), functionally defined
as transcripts >200 nt in length with no protein-coding
potential, continues to grow. Researchers have discovered
many of these lncRNAs are uniquely expressed in
differentiated tissues or specific cancer types. It is now
established that lncRNAs are exquisitely controlled and
www.impactjournals.com/oncotarget

SUSTAINING PROLIFERATION
In normal tissue, the production and release of
cellular growth signals is tightly controlled, ensuring
homeostasis and balance in the cellular population.
12517
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Dysregulation of such signaling leads to malignancy.
Uncontrolled gene transcription with resultant protein
production may increase cellular proliferation, but
excess proliferative signaling may in turn trigger cellular
senescence. Cancer cells may also sustain proliferation
by evading growth suppressors. For instance, the RB
protein is pivotal in negative control of the cell cycle
and tumor progression. TP53 proteins control cellular
division and prevent uncontrolled growth-and-division by
activating apoptosis and preventing cell-cycle progression
[5]. In recent years, the role of lncRNAs in sustaining

proliferation of CRC cells has garnered great interest
(Table 2).
LncRNA colon cancer-associated transcript
1(CCAT1) is a recently discovered 2628 nucleotidelncRNA, located in the vicinity of c-Myc. He et al
discovered that c-Myc could promote CCAT1 transcription
by directly binding to its promoter region, and enhanced
CCAT1 expression in CRC cells cells increased cell
proliferation and invasion [6]. Moreover, Takahashi et al
reported lncRNA Plasmacytoma variant translocation 1
(PVT-1) expression is increased by amplification of 8q24

Figure 1: The functions of lncRNA in colorectal cancer pathogenesis. LncRNAs have multiple functions in the context of

colorectal cancer, including increasing proliferation, angiogenesis, metastasis, invasion, apoptosis, stemness, and genomic instability. Red
arrows indicate promoted signaling pathways. Blue arrows indicate inhibited signaling pathways. Some LncRNAs have multiple functions
(for example, CCAT2 promotes proliferation, metastasis, and genomic instability). Abbreviations: CCAT2: colon cancer-associated
transcript 2; CCAT1: LncRNA colon cancer-associated transcript 1; BANCR: BRAF-activated lncRNA; TUG1: Taurine up-regulated gene
1; FEZF1-AS1: long noncoding RNA FEZF1 antisense RNA1; CASC11: cancer susceptibility candidate 11; CRNDE: Colorectal Neoplasia
Differentially Expressed; UCA1:urothelial carcinoma-associated 1 ;MEG3: maternally expressed gene 3; MALAT1: metastasis associated
lung adenocarcinoma transcript 1; ANRIL: Antisense noncoding RNA in the INK4 locus; HOTAIR: Hox transcript antisense intergenic
RNA; HOTTIP: ‘HOXA transcript at the distal tip’
www.impactjournals.com/oncotarget
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Table 1: A summary of lncRNAs involved in colorectal cancer development and progression
LncRNA

In colorectal
cancer, its
expressions is:

Functions

Reference

Colon Cancer Associated
Transcript 1 (CCAT1)

Upregulated

Promotes cellular proliferation, migration, and
invasion.

[6]

Plasmacytoma variant
translocation 1(PVT-1)

Upregulated

Promotes proliferation and invasion. Knockdown of
PVT-1 promotes apoptosis in colorectal cancer cell
lines by activating the TGF-β signaling pathway.

[7]

Colorectal Neoplasia
Differentially Expressed
(CRNDE)

Upregulated

Promotes colon cancer cell proliferation.

[8, 9, 10]

Metastasis Associated Lung
Adenocarcinoma Transcript
1 (MALAT1)

Upregulated

Promotes cellular proliferation, migration, and
invasion via 1) binding to SFPQ and releasing
oncogene PTBP2 from SFPQ/PTBP2 complex 2)
increasing expression of AKAP-9 via promoting
SRPK1-catalyzed SRSF1 phosphorylation in
colorectal cancer cells.

[11, 12, 13]

ZNFX1 antisense RNA 1
(ZFAS1)

Upregulated

Silencing of ZFAS1 decreases CRC cell
proliferation via G1-arrest of the cell cycle and
decreasing CRC tumorigenicity. ZFAS1 acts as
an oncogene in CRC via 1) destabilization of p53;
2) interaction with CDK1/cyclin B1 complex
leading to cell cycle progression and suppression
of apoptosis.

[14, 15, 16, 17]

MYC-induced lncRNAs
(MYCLo-1, MYCLo-2,
MYCLo-3)

Upregulated

Promotes MYC-modulated cell proliferation.
MYCLo-1/-2 promote G1/S transition. MYCLo-3
decreases cellular time spent in the S and G2 phases.

[18]

Downregulated

Inhibits MYC-enhanced cell proliferation.
MYCLo-4/-6 increase G2 arrest. MYCLo-5
decreases cellular populations in the S phase.

[19]

Antisense noncoding RNA in
the INK4 locus (ANRIL)

Upregulated

Promotes proliferation in a p15/p16-pRB pathwayindependent manner, and promotes cell invasion
and migration.

[20, 61]

urothelial carcinomaassociated 1 (UCA1)

Upregulated

Activates proliferation, suppresses apoptosis
and cell cycle progression of CRC cells. UCA1
induces CRC migration and invasion and predicts
poor prognosis.

[21, 22, 23]

BRAF-activated lncRNA
(BANCR)

Downregulated

Inhibits the proliferation in part through
upregulation of p21, induces the epithelialmesenchymal transition (EMT) through an MEK/
extracellular signal-regulated kinase-dependent
mechanism.

[24, 33]

Maternally expressed gene 3
(MEG3)

Downregulated

Inhibits CRC cell proliferation and is an
independent predictor for overall survival.

[25]

LncRNA loc285194

Downregulated

Suppresses tumor cell growth due to specific
suppression of miR-211. Low expression of
LOC285194 is associated with larger tumor size,
higher tumor stage, more distant metastasis and
poorer disease free survival.

[26, 27, 28]

MYC-repressed lncRNAs
(MYCLo-4, MYCLo-5,
MYCLo-6)

www.impactjournals.com/oncotarget
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LncRNA

In colorectal
cancer, its
expressions is:

Functions

Reference

Loc554202

Downregulated

Suppresses the cell proliferation, induces
apoptosis, partly through activating specific
caspase cleavage cascades, and inhibits CRC
tumorigenesis.

[32]

LncRNA H19

Upregulated

Promotes EMT in CRC.

[34]

Hox transcript antisense
intergenic RNA (HOTAIR)

Upregulated

Indicates poorer prognosis, promotes migration and
invasion, enhances CSC properties, promotes cellular
proliferation, decreases the expression of E-cadherin
and increases expression of vimentin and MMP9.

[36, 49]

HOTTIP(‘HOXA transcript
at the distal tip’ )

Upregulated

Predicts unfavorable prognosis for CRC patients.

[37]

Taurine up-regulated gene 1
(TUG1)

Upregulated

Increases the invasive and metastatic ability of
CRC cells through activating EMT process and
TUG1 overexpression indicates poor survival rates
and a higher risk for cancer metastasis.

[38]

FEZF1 antisense RNA1
(FEZF1-AS1)

Upregulated

Promotes migration and proliferation through
activating the G1-S checkpoint

[39]

Cancer susceptibility
candidate 11 (CASC11)

Upregulated

Promotes CRC cell proliferation and metastasis by
activation of WNT/β-catenin signaling.

[40]

91H

Upregulated

Promotes the proliferation, migration, and
invasiveness of CRC cells.

[41]

LncRNA-CTD903

Downregulated

Predicts favorable prognosis in CRC patients
and suppresses invasion and migration through
repressing Wnt/β-catenin signaling.

[42]

LncRNA TINCR

Downregulated

Suppresses CRC proliferation and metastasis by
accelerating the cleavage of EpCAM and releases
EpICD via activating WNT/β- catenin pathway.

[43]

ncRAN

Downregulated

Inhibits in vitro migration and invasion of CRC
cells and predicts CRC patient outcome.

[44]

Colon cancer-associated
transcript 2 (CCAT2)

Upregulated

Promotes tumor growth, metastasis, and
chromosomal instability. It functions as a WNT
downstream target.

[46]

LncRNA-HIF2PUT

Upregulated

Promotes the HIF-2α expression and the CSC
properties.

[48]

Lnc34a(locus mainly in the
nucleus)

Upregulated

Enhances CSC self-renewal and tumorigenesis and
suppresses miR-34a expression.

[50]

Downregulated

Attenuates the viability, self-renewal, and
glycolysis of CSCs.

[51]

Upregulated

Serves as a potential prognosis predictor for CRC
prognosis, associates with TNM stage, histologic
grade, and lymph node metastasis, and predicts
shorter overall survival and disease-free survival
time.

[52]

LincRNA-p21
LncRNA DANCR

(Continued )
www.impactjournals.com/oncotarget
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LncRNA

In colorectal
cancer, its
expressions is:

Functions

Reference

LncRNA FTX

Upregulated

Serves as an independent prognostic factor for
CRC patients and is associated with differentiation
grade, lymph vascular invasion, and clinical stage;
indicates poorer overall survival.

[53]

Prostate cancer associated
transcript 1(PCAT-1)

Upregulated

Functions as an independent prognostic factor
for CRC patient outcome and implicates poorer
overall survival.

[54, 55]

Downregulated

Serves as a prognosis indicator for CRC patients.
Its down-regulation indicates increased distant
metastasis and a poor disease-free survival.

[56]

PRNCR1

Upregulated

Serves as a sensitive diagnostic biomarker of CRC.

[57]

NEAT1

Upregulated

Functions as s diagnostic and prognostic
biomarker of overall survival in CRC, associates
with tumor differentiation, invasion, metastasis
and TNM stage and predicts shorter disease-free
survival time and overall survival time.

[58, 59]

RP11-462C24.1

Table 2: LncRNAs involved in sustained proliferation of CRC
LncRNA

In colorectal cancer, its
expressions is:

Functions

Reference

LncRNA

Expression

Functions

Reference

CCAT1

Upregulated

Promotes colon cancer cell proliferation.

[6]

PVT-1

Upregulated

Promote proliferation and invasion;
Knockdown of PVT-1 promotes
apoptosis in colorectal cancer cell lines
by activating the TGF-β signalling
pathway.

[7]

CRNDE

Upregulated

Promotes colon cancer cell proliferation.

[8, 9, 10]

MALAT1

Upregulated

Promotes cellular proliferation,
migration, and invasion via 1) binding
to SFPQ and releasing oncogene
PTBP2 from SFPQ/PTBP2 complex 2)
increasing expression of AKAP-9 via
promoting SRPK1-catalyzed SRSF1
phosphorylation in colorectal cancer
cells.

[11, 12, 13]

ZFAS1

Upregulated

Silencing of ZFAS1 decreases CRC
cell proliferation via G1-arrest of
the cell cycle and decreasing CRC
tumorigenicity. ZFAS1 acts as an
oncogene in CRC via 1) destabilization
of p53; 2) interaction with CDK1/
cyclin B1 complex leading to cell
cycle progression and suppression of
apoptosis.

[14, 15, 16, 17]

(Continued )
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LncRNA

In colorectal cancer, its
expressions is:

Functions

Reference

Upregulated

Promotes MYC-modulated cell
proliferation. MYCLo-1/-2 promote
G1/S transition. MYCLo-3 decreases
cellular time spent in the S and G2
phases

[18]

Downregulated

Inhibits MYC-enhanced cell
proliferation. MYCLo-4/-6 increase
G2 arrest. MYCLo-5 decreases cellular
populations in the S phase.

[19]

ANRIL

Upregulated

Promotes proliferation in a p15/p16pRB pathway-independent manner.

[20]

UCA1

Upregulated

Activates proliferation, suppresses
apoptosis and cell cycle progression of
CRC cells.

[21, 22, 23]

BANCR

Downregulated

Inhibits the proliferation in part through
upregulation of p21

[24]

Maternally
expressed gene 3
(MEG3)

Downregulated

Inhibits CRC cell proliferation and
serves as an independent predictor for
overall survival.

[25]

LncRNA
loc285194

Downregulated

Suppresses tumor cell growth due to
specific suppression of miR-211. Low
expression of LOC285194 shows larger
tumor size, higher tumor stage, more
distant metastasis and poorer disease
free survival.

[26, 27, 28]

Loc554202

Downregulated

Inhibits the cell proliferation and
induces apoptosis, partly through
activating specific caspase cleavage
cascades.

[32]

Upregulated

Promotes proliferation through
activating the G1-S checkpoint.

[39]

MYC-induced
lncRNAs
(MYCLo-1,
MYCLo-2,
MYCLo-3)
MYC-repressed
lncRNAs
(MYCLo-4,
MYCLo-5,
MYCLo-6)

Long noncoding
RNA FEZF1
antisense RNA1
(FEZF1-AS1)

copy-number. CRC cells transfected with PVT-1 specific
siRNA exhibited significant proliferative and invasive
capability loss [7], supporting PVT-1 as a potential
carcinogenic lncRNA in CRC. Another oncogenic lncRNA
regulating CRC proliferation is Colorectal Neoplasia
Differentially Expressed (CRNDE) [8], which is located
on chromosome 16 of the human genome. It shares a bidirectional promoter with iroquois homeobox 5 (IRX5),
which is adjacent at the opposite strand. The expression of
CRNDE is tissue-specific, and follows a temporal pattern.
Rarely is CRNDE observed in adult colorectal mucosa,
liver, and white blood cells, and increased CRNDE
expression occurs in the testis, breast, and skin [9].
Additionally, CRNDE expression is significantly increased
www.impactjournals.com/oncotarget

in several neoplastic diseases, including colorectal cancer.
There are two existing CRNDE transcripts: cytoplasmic
(fully spliced and free of intron sequences) and nuclear
(the intron sequences) transcripts. Insulin, IGF1, and
IGF2 do not increase or decrease cytoplasmic CRNDE
transcripts, but decrease nuclear CRNDE transcripts via
both the PI3K/Akt/mTOR and Raf/MAPK pathways.
Knockdown of gVC-In4, a highly-conserved region of
CRNDE, affects insulin signaling responses, as well as
many genes associated with glucose/lipid metabolism.
Several other insulin-regulated genes are affected by
gVC-In4 knockdown as well. GLUT4, an insulinregulated glucose transporter, translocates to the plasma
membrane, allowing intracellular glucose transport.
12522
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CRNDE increases GLUT4 and MLXIPL transcription.
gVC-In4 knockdown decreases glucose intake, thereby
causing less lactate secretion. The increased expression
of CRNDE nuclear transcripts promotes glucose
metabolism, lactate secretion, and lipid synthesis in CRC
cells. CRNDE nuclear transcripts influence upstream
insulin/IGF signaling pathways. Thus CRNDE nuclear
transcripts, which are inhibited by insulin, IGF1, and
IGF2 via PI3K/Akt/mTOR and Raf/MAPK pathways,
promote central metabolism [10]. Another well known
lncRNA overexpressed in CRC is the human metastasis
associated lung adenocarcinoma transcript 1 (MALAT1)
[11]. Xu et al first reported that one fragment (6918 nt8441 nt, located at the 3’ end) of MALAT-1 is influential
in the biological processes of cell proliferation, migration,
and invasion [11]. Several mechanisms connect MALAT1
to CRC cellular proliferation. It has been reported that
MALAT1 overexpression enhances cell proliferation
and migration in vitro, and promotes tumor growth
and metastasis in nude mice, due to tumor suppressor
gene SFPQ and proto-oncogene PTBP2. MALAT1
binds SFPQ, releasing PTBP2 from the SFPQ/PTBP2
complex. In turn, increased levels of SFPQ-detached
PTBP2 promote cell proliferation and migration. In this
sense, SFPQ mediates the regulatory effects of MALAT1
[12]. Furthermore, MALAT1 interacts with both SRPK1
and SRSF1. MALAT1 increases AKAP-9 expression by
promoting SRPK1-catalyzed SRSF1 phosphorylation.
After MALAT1 knockdown, overexpression of
SRPK1 restored SRSF1 phosphorylation and AKAP-9
expression, promoting cell proliferation, invasion, and
migration in vitro. Conversely, SRPK1 knockdown after
overexpression of MALAT1 in a CRC cell line reduced
SRSF1 phosphorylation and AKAP-9 expression, and
inhibited cell proliferation, invasion, and migration in
vitro. These findings suggest MALAT1 increases AKAP9 expression by promoting SRPK1-catalyzed SRSF1
phosphorylation in CRC cells [13].
Thorenoor et al recently profiled expression of
disease-associated lncRNAs in CRC tumor tissues and
identified ZFAS1 (zinc finger antisense 1), previously
known to be a tumor suppressor gene in human breast
cancer [14, 15] and oncogene in hepatocellular carcinoma
[16], to be overexpressed in CRC tissue. ZFAS1 silencing
reduced CRC cell proliferation through G1-arrest of cell
cycle, and also tumorigenicity of CRC cells. Via RIP
(RNA immunoprecitation) analysis, the authors identified
Cyclin-dependent kinase 1 (CDK1) as an interacting
partner of ZFAS1. Through bioinformatics analysis, the
authors found that ZFAS1 could sponge miR-590-3p,
which targets CDK1. The authors further demonstrated
ZFAS1 activates CDK1 and cyclin B1. When ZFAS1
is silenced, cyclin B1 is decreased. ZFAS1 silencing
activates P53 and PARP cleavage, increasing CRC cell
apoptosis. Taken together, ZFAS1 advances cell cycle
progression and inhibits apoptosis, via activation of P53
www.impactjournals.com/oncotarget

and CDK1/cyclin B1 complex, thus critical for CRC cell
viability, cell cycle distribution, apoptosis, and colony
formation [17]. Kim recently identified MYCLos as a key
molecule in CRC cell cycle regulation and tumorigenesis,
by influencing MYC target genes such as CDKN1A (p21)
and CDKN2B (p15) [18]. RNA binding proteins HuR and
hnRNPK are involved in the function of MYCLos, by
respectively interacting with MYCLo-1 and MYCLo-2.
Knockdown of MYCLo-2, differentially expressed in
CRC, inhibits cancer transformation and tumorigenesis
[18]. The same research group later characterized another
three MYC-repressed lncRNAs named MYCLo-4, -5,
and -6. The MYC-repressed MYCLos were proved to
suppress cell cycle progression, and therefore inhibiting
cell proliferation. Through screening all cell cycle-related
genes affected by MYC and MYC-repressed MYCLos, the
MYC-repressed gene GADD45A has been identified to be
a target gene of MYCLo-4 and MYCLo-6 [19].
ANRIL is a lncRNA transcribed from the INK4
locus, and encodes three tumor suppressor genes
(p15, p16, and ARF). ANRIL represses p15 and p16,
which positively regulate the pRB pathway, repressing
senescence of normal human fibroblasts [20]. However,
the role of ANRIL in cancer cell proliferation is not well
understood. Naemura et al reported ANRIL increased
proliferation of colorectal cancer HCT116 cells in twoand three-dimensional cultures. Silencing ANRIL by
siRNA and retroviral-produced shRNA decreased HCT116
cell proliferation in both two- and three-dimensional
cultures. HCT116 cells depleted of ANRIL were arrested
in the S phase of the cell cycle. Notably, silencing ANRIL
did not activate expression of the INK4 locus. These
observations suggest ANRIL increases proliferation of
HCT116 cells in two- and three-dimensional cultures via
p15/p16-pRB [20].
The lncRNA urothelial carcinoma-associated 1
(UCA1) is significantly overexpressed in most tumor
tissues and cancer cells. Han et al demonstrated UCA1
levels were markedly increased in CRC tissues and cells
compared to control, and the level of UCA1 expression
was positively correlated with tumor size, poor histological
differentiation, and increased tumor depth. Increased
UCA1 expression carried significantly poorer prognosis
and overexpression of UCA1 increases proliferation, and
decreases apoptosis and cell cycle progression of CRC
cells [21]. Ni et al further demonstrated that increased
UCA1 expression was positively correlated to lymph
node metastasis, distant metastasis, and tumor stage.
Survival analysis revealed correlation between increased
UCA1 expression and poor prognosis. Moreover,
multivariate analysis identified UCA1 overexpression as
an independent predictor for CRC. UCA1 knockdown
significantly decreased CRC proliferation and metastasis.
Flow cytometry assays demonstrated UCA1 silencing
induced G0/G1 growth arrest and apoptosis of CRC
cells. To further investigate the regulatory mechanisms
12523
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of UCA1, the authors identified that Ets-2 bound to the
UCA1 core promoter using luciferase assays [22]. This
observation suggested that UCA1 might be an important
prognostic predictor in CRC and might be considered as a
potential target for CRC diagnosis and gene therapy. More
recently, Bian et al reported UCA1 sponged endogenous
miR-204-5p, thereby inhibiting its activity in CRC, and
identified CREB1 as a new target of miR-204-5p. The
protein levels of CREB1 were significantly increased in
CRCs, positively correlated with UCA1 expression, and
negatively associated with survival. Taken together, Bian
et al’s work demonstrated existence of a UCA1-miR-2045p-CREB1/BCL2/RAB22A regulatory network in CRC,
supporting UCA1 and CREB1 as potential new oncogenes
and prognostic factors for CRC [23].
LncRNAs may serve as tumor suppressors inhibiting
CRC cellular proliferation. BRAF-activated non-coding
RNA (BANCR) was first discovered during an RNAseq screen for transcripts influenced by the expression
of the oncogene BRAFV600E. Shi et al demonstrated
significantly decreased expression of BANCR in three
colorectal cancer cell lines. Suppression of BANCR
increases proliferation of colorectal cancer cells, partly
via downregulation of p21 [24]. Maternally expressed
gene 3 (MEG3) is another lncRNA that functions as a
CRC proliferative suppressor. Yin et al reported decreased
MEG3 levels correlated positively with low histological
grade, increased tumor invasion, and advanced tumor
node metastatic (TNM) stage CRC disease. Multivariate
analyses revealed that MEG3 expression served as
an independent predictor for overall survival. Further
experiments demonstrated MEG3 overexpression
significantly inhibited CRC cell proliferation both in vitro
and in vivo [25].
Two lncRNAs have recently been identified as CRC
proliferation inhibitors. Pasic et al first reported in 2010
lncRNA loc285194 to be within a tumor suppressor unit
in osteosarcoma, and suppressed tumor cell growth [26].
Another research group demonstrated LOC285194 to
be decreased in tumor tissues and colorectal cancer cell
lines compared to normal intestinal mucous cell lines.
Additionally, low levels of LOC285194 were correlated
with larger tumor size, increased tumor stage, more distant
metastasis, and decreased disease-free survival [27]. Liu
et al demonstrated loc285194 is a p53 transcription target,
and ectopic expression of loc285194 inhibits tumor cell
growth both in vitro and in vivo. Through deletion analysis,
Liu et al identified an active region responsible for tumor
cell growth inhibition within exon 4, which harbors two
miR-211 binding sites. This loc285194-mediated growth
inhibition is partially due to specific suppression of miR211 [28]. The second newly discovered CRC inhibitor
lncRNA is loc554202. Loc554202 is a 2166-bp transcript
on human chromosome 9p21.3, previously shown to be
dysregulated in breast and lung cancer [29–31]. Ding et
al reported expression of Loc554202 was significantly
www.impactjournals.com/oncotarget

inhibited in CRC cell lines compared to normal human
intestinal epithelial cell lines. Decreased loc554202
expression was associated with advanced pathologic stage
and a larger tumor size. Moreover, loc554202 expression
decreased cellular proliferation, induced apoptosis in vitro,
and hindered tumorigenesis in vivo, partly via specific
caspase cleavage cascade activation [32].

ACTIVATING METASTASIS/INVASION
PROGRAM
Although primary CRC can be treated by
surgical resection, patient survival deteriorates once
metastasis to vital organs (such as the liver or lungs) has
occurred. Primary CRC develops progressively through
accumulation of genetic mutations (e.g., APC, KRAS, p53,
SMAD4, and PTEN) and epigenetic silencing of tumor
suppressor genes. Mounting evidence suggests lncRNAs
influence the invasive and metastatic potential of CRC
(Figure 2 and Table 3). For instance, Guo et al. determined
BANCR is overexpressed in CRC tissues, correlating
with increased lymph node metastasis and tumor stage.
While ectopic BANCR expression increased migration of
human CRC Caco-2 cells, BANCR knockdown inhibited
in vitro HCT116 cell migration [33], via induction of
the epithelial-mesenchymal transition (EMT) through
a MEK/extracellular signal-regulated kinase-dependent
mechanism. These results suggest BANCR is essential
for CRC metastasis, with great potential therapeutic value
against CRC progression.
The lncRNA H19, a known oncogene in various
cancer types, tumorigenesis and cancer progression. Liang
et al recently characterized H19 as a novel regulator of
epithelial-to-mesenchymal transition (EMT) in CRC.
H19 is highly expressed in mesenchymal-like cancer
cells and primary CRC tissues. Stable H19 expression
promotes EMT progression and accelerates in vivo and
in vitro tumor growth. Bioinformatics in combination
with RIP analysis revealed H19 functions as a competing
endogenous RNA (ceRNA) for miR-138 and miR200a, antagonizing their function, and activating their
endogenous targets Vimentin, ZEB1, and ZEB2, all
key marker genes of mesenchymal cells. In summary,
lncRNA H19 is involved in EMT program as a competing
endogenous RNA, ultimately contributing to CRC
progression [34].
HOTAIR (the Hox transcript antisense intergenic
RNA), is a lncRNA expressed from the developmental
HOXC locus located on chromosome 12q13.13. Kogo
et al reported HOTAIR expression levels were higher
in cancerous tissues than in noncancerous tissues, and
increased HOTAIR expression correlated positively
with the liver metastasis. Moreover, patients expressing
increased HOTAIR levels had poor prognosis. In a subset
of 32 CRC specimens, gene set enrichment analysis
using cDNA array data revealed a close correlation
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between expression of HOTAIR and members of the
PRC2 complex (SUZ12, EZH2, and H3K27me3) [35].
Wu et al more recently demonstrated HOTAIR was
associated with epithelial-mesenchymal transition in CRC,
reporting HOTAIR depletion increased the expression of
E-cadherin while concomitantly decreasing expression
of vimentin and MMP9 [36]. Upregulation of HOTAIR
might be a critical element contributing to CRC metastatic
progression. LncRNA taurine up-regulated gene 1
(TUG1) has been reported to be correlated with cancer
progression. Sun et al specifically analyzed TUG1 in the
context of CRC, and demonstrated TUG1 expression
was significantly increased in CRC cell lines, suggesting
TUG1 downregulation may be a negative prognostic
factor for CRC patients. TUG1 may increase the invasive
and metastatic ability of CRC cells, at least in part through
influencing the EMT process [38].
LncRNA FEZF1 antisense RNA1 (FEZF1-AS1)
was recently corroborated to be significantly oveexpressed
in human primary CRC, and is associated with CRC
metastasis and poor prognosis. Moreover, suppression
of FEZF1-AS1 expression significantly inhibited CRC
cell proliferation, migration and invasiveness, suppressed
S-phase entry in vitro, and repressed tumor growth and
metastasis in vivo. FEZF1-AS1 overexpression increased
malignant aspects of CRC cells. Dysregulation of FEZF1-

AS1 therefore participates in CRC tumorigenesis and
progression [39]. Moreover, The overexpression of
FEZF1-AS1 leads to significant cells reduction at G0/G1phase and increase in S-phase. Conversely, knockdown of
FEZF1-AS1 does just the opposite. FEZF1-AS1 induces
CRC cell proliferation by activating the G1-S checkpoint
[39].
Cancer susceptibility candidate 11 (CASC11) is
overexpressed in CRC tissues and is positively associated
with tumor size, serosal invasion, lymph metastasis, and
tumor-node-metastasis (TNM) stage. CASC11 promotes
CRC cell proliferation and metastasis in vitro and in
vivo. CASC11 increases expression of heterogeneous
ribonucleoprotein K (hnRNP-K) and β-catenin nuclear
accumulation, activating WNT/β-catenin signaling in
CRC cells [40]. Additionally, c-Myc directly binds the
promoter regions of CASC11, increasing promoter histone
acetylation, augmenting CASC11 expression. CASC11
has potential as a diagnostic biomarker, and may be an
effective therapeutic against CRC. In addition, located
on the H19/IGF2 locus (119.329 kbs long), 91H (H19
antisense RNA) is a lncRNA which is overexpressed
in CRC tissue and cell lines. 91H overexpression is
correlated with increased metastasis and poor prognosis.
Multivariate analysis demonstrates 91H expression is an
independent prognostic and metastatic indicator of CRC.

Figure 2: The regulation of metastasis by lncRNA. Red arrows indicate promoted signaling pathways; blue arrows indicate
inhibited signaling pathways. Several lncRNAs (such as CCAT1, ANRIL, 91H, FEZF1-AS1, and ncRNA) have unknown mechanisms.
www.impactjournals.com/oncotarget
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Table 3: LncRNAs participate in metastasis/invasion-promoting programs of CRC
LncRNA

In colorectal cancer, its
expressions is:

Functions

Reference

CCAT1

Upregulated

Promotes cell migration and
invasion.

[6]

BANCR

Upregulated

Induces EMT program through an
MEK/extracellular signal-regulated
kinase-dependent mechanism.

[33]

LncRNA H19

Upregulated

Promotes EMT in CRC.

[34]

HOTAIR

Upregulated

Promotes migration and invasion,
decreases expression of E-cadherin,
increases expression of vimentin
and MMP9 and associates with
poorer prognosis.

[36]

TUG1

Upregulated

Increases the invasive and
metastatic ability of CRC cells
through activating EMT process

[38]

FEZF1-AS1

Upregulated

Promotes migration.

[39]

CASC11

Upregulated

Promotes CRC cell metastasis,
dependent on activation of WNT/βcatenin signaling.

[40]

91H

Upregulated

Promotes proliferation, migration,
and invasiveness of CRC cells.

[41]

LncRNA-CTD903

Downregulated

Suppresses invasion and migration
through repressing Wnt/β-catenin
signaling.

[42]

LncRNA TINCR

Downregulated

Suppresses CRC proliferation
and metastasis by accelerating the
cleavage of EpCAM and releasing
EpICD via activating WNT/βcatenin pathway.

[43]

ncRAN

Downregulated

Inhibits migration and invasion of
CRC cells.

[44]

ANRIL

Upregulated

Promotes cell invasion and
migration.

[61]

Moreover, knockdown of 91H inhibited the proliferation,
migration, and invasiveness of CRC cells [41].
Several lncRNAs that suppress metastasis were
recently discovered. lncRNA-CTD903 is an independent
predictor of favorable prognosis in CRC patients. After
knockdown of CTD903 in CRC cell lines, CRC cells
were noted to exhibit EMT-like appearance, decreased
adherence ability, and increased invasion and migration
characteristics. Inhibition of CTD903 increased Wnt/βcatenin activation, increased transcription factors Twist
and Snail expression, increased mesenchymal marker
Vimentin, and decreased epithelial marker ZO-1.
LncRNA-CTD903 is therefore likely a suppressor of
metastasis in CRC via Wnt/β-catenin signaling repression
www.impactjournals.com/oncotarget

[42]. Another suppressor of CRC metastasis is TINCR, a
3.7 kb lncRNA. TINCR levels are negatively correlated
with CRC progression, tumor growth, and metastasis
(both in vivo and in vitro). During physiologic conditions,
TINCR binds EpCAM. Loss of TINCR increases
hydrolysis of EpCAM, increases release of EpICD, and
activates the Wnt/β-catenin pathway. c-Myc decreases
TINCR expression via repression of sp1-transcriptive
activity, establishing a positive feedback loop controlling
c-Myc and TINCR expression. Loss of TINCR expression
promotes proliferation and metastasis in CRC, and is
therefore a potential cancer suppressor gene [43]. ncRNA
(non-coding RNA expressed in aggressive neuroblastoma)
has previously been demonstrated to be overexpressed and
12526
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associated with poor prognosis in human neuroblastoma,
as well as bladder cancer. However, ncRAN is
significantly decreased in CRC tumor tissue and CRC
cell lines. Moreover, expression of ncRAN is inhibited
in poorly differentiated or undifferentiated CRC tumors,
and in CRC tumors with liver metastases. Multivariate
analysis demonstrates decreased ncRAN expression is an
independent predictor of overall survival. Taken together,
these data suggest ncRAN may be a biomarker for early
CRC metastasis, a prognostic indicator, and a therapeutic
target against CRC [44].

residual disease, and tumor recurrence. However, the
molecular hallmarks of CSCs in colorectal cancer remain
unelucidated. While lncRNAs have been identified to be
intimiately involved with various malignancies, their role
in stemness maintenance in CRC remain the subject of
intense study (Table 5).
The lncRNA “lncRNA-HIF2PUT” is a promoter
upstream transcript of hypoxia-inducible factor-2α
(HIF-2α) in CRC. The function of HIF-2α is closely
connected with “stem cell-like” properties, and the
function of promoter upstream transcripts (PROMPTs)
is often associated with the adjacent protein-coding
transcripts. lncRNA-HIF2PUT expression is correlated
with HIF-2α levels in CRC tissues; knockdown of
lncRNA-HIF2PUT blocked HIF-2α expression, and
inhibited CSC properties in CRC cell lines. Knockdown
of LncRNA-HIF2PUT via siRNA decreased expression
of stemness genes, impaired colony formation, decreased
spheroid formation ability, retarded migration, and
decreased invasiveness [48]. The well-known lncRNA
HOTAIR also participates in stemness maintenance in
CRC. Dou et al demonstrated CD133(+)-shHOTAIR
exhibited decreased cellular proliferation, migration,
invasion, colony-forming properties of in vitro CRC cells,
as well as decreased Vimentin expression with increased
E-cadherin expression. Down-regulation of HOTAIR
expression in CD133(+) CSCs markedly decreased tumor
growth and lung metastasis in xenograft nude mice [49].
Therefore, HOTAIR may be a potential therapeutic target
against CRC CSCs. In addition, the lncRNA Lnc34a is
abundant in the CSCs of CRC, and initiates asymmetric
division by directly targeting miR-34a, disrupting
spatial balance. Lnc34a recruits Dnmt3a via PHB2 and
HDAC1, methylating and deacetylating the miR-34a
promoter simultaneously, epigenetically silencing miR34a expression independent of its upstream regulator,
p53. Lnc34a levels increase CRC CSC self-renewal and
CRC growth in xenograft models. Moreover, lnc34a is
overexpressed in late-stage CRCs, causing epigenetic
miR-34a silencing and CRC proliferation [50]. Wang et
al recently identified lincRNA-p21 (large intergenic noncoding RNA p21) is a potent suppressor of the stem-like
traits of CSCs purified from both primary CRC tissues and
cell lines. LincRNA-p21 inhibited β-catenin signaling,
thereby decreasing viability, self-renewal, and glycolysis
of CSCs in vitro. Administration of Ad-lnc-p21-MRE
significantly decreased the self-renewal potential and
tumorigenicity of CSCs in nude mice [51]. In this sense,
lincRNA-p21 might be promising therapeutic against
CSCs in CRC.

GENOME INSTABILITY
All organisms require faithful propagation of
genetic material and transmission into progeny cells,
and avoidance of mutation propagation that may lead
to genomic instability and aberrant cellular activity.
Various DNA insults may occur by extrinsic factors
such as ultraviolet (UV) radiation, ionizing radiation
(IR), and numerous genotoxic chemicals [45]. In cancer
cells, the rates of mutation increase due to breakdown
of the genomic maintenance machinery. Despite cancer
cell adaptation to this increased mutation rate, there is
inevitably genomic instability within tumors themselves.
Unfortunately, few investigations have identified potential
lncRNAs involved in this process in CRC (Table 4). Ling
et al reported that colon cancer-associated transcript 2
(CCAT2), a novel lncRNA encompassing the rs6983267
SNP, was overexpressed in microsatellite-stable colorectal
cancer and promoted tumor growth, metastasis, and
chromosomal instability. MYC, miR-17-5p, and miR20a are upregulated by CCAT2 via TCF7L2-mediated
transcriptional regulation. The interaction between CCAT2
and TCF7L2 enhances WNT signaling. As CCAT2 is a
WNT downstream target, a feedback loop likely exists.
SNP status affects CCAT2 expression, and allele G
increases CCAT2 transcript production. CCAT2 activates
WNT signaling by enhancing TCF7L2 transcriptional
activity to increase MYC expression. CCAT2 transcription
increases WNT target gene expression by binding TCF7L2
and modulating its transcriptional activity. CCAT2 likely
promotes chromosomal instability and tumor growth by
activating WNT signaling and increasing MYC expression
via activation of CDC25A, miR-17-5p, and miR-20a) [46].

STEMNESS
CRC has been recently identified to encompass
a subset of cells with stem/progenitor cell features
known as cancer stem cells (CSCs), which could lead
to advanced tumors and a poor prognosis [47]. Because
CSCs contribute to tumor-initiating potential, invasion,
metastasis, resistance to traditional therapies, and eventual
relapse, the CSC model explains clinical events previously
a mystery, including therapy resistance, minimal
www.impactjournals.com/oncotarget

CLINICAL APPLICATION
LncRNAs emerge from a previously overlooked
region of the genome, as a novel source of potentially
useful biomarkers characterizing disease progression,
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Table 4: Genome instability-related lncRNAs
LncRNA

In colorectal cancer, its
expressions is:

Functions

Reference

Upregulated

Increases chromosomal instability.

[46]

CCAT2

Table 5: LncRNAs associated with stemness mantenance in CRC
lncRNA

In colorectal cancer, its
expressions is:

Functions

Reference

LncRNA-HIF2PUT

Upregulated

Enhances the HIF-2α expression
and promotes CSC properties.

[48]

LncRNA HOTAIR

Upregulated

Promotes CSC properties, increases
cellular proliferation, migration,
invasion, colony-forming.

[49]

Lnc34a(locus mainly in the
nucleus)

Upregulated

Enhances CSC self-renewal and
tumorigenesis and suppresses miR34a expression.

[50]

Downregulated

Attenuates the viability, selfrenewal, and glycolysis of CSCs.

[51]

LincRNA-p21

recurrence, and prognosis. The fact lncRNA expression
levels are typically markedly increased or decreased
depending upon disease state makes them ideal for
useful clinical application. Most importantly, as we
discover the mechanisms of their involvement in CRC,
their applicability as therapeutics against CRC may be
determined (Table 6).
LncRNAs have been intensively investigated for
their role in predicting CRC prognosis. Liu et al reported
that lncRNA DANCR expression was significantly
increased in CRC tissues compared to adjacent normal
tissues. Increased lncRNA DANCR expression was
negatively correlated with TNM stage, histologic grade,
and lymph node metastasis. Moreover, increased lncRNA
DANCR expression was associated with decreased
overall and disease-free survival for CRC patients [52].
Therefore, lncRNA DANCR expression holds potential as
a prognosis predictor for CRC. FTX is another lncRNA
with prognostic potential in CRC. FTX was significantly
overexpressed in CRC tissues. Decreased FTX expression
is associated with decreased differentiation grade,
lymphatic vascular invasion, and clinical stage. Further
multivariate analyses revealed that increased FTX levels
serves as an independent prognostic factor for CRC patient
survival [53].
LncRNA PCAT-1 (prostate cancer-associated
ncRNA transcripts 1) is involved with human prostate
cancer progression [54]. Ge et al demonstrated markedly
increased PCAT-1 expression in CRC tissues. Increased
PCAT-1 levels are associated with distant metastasis, and
poorer overall survival. Multivariable Cox regression

www.impactjournals.com/oncotarget

analysis identified PCAT-1 overexpression is an
independent prognostic factor for CRC outcome. [55].
Some lncRNAs may also hold promise in the
future as novel diagnostic biomarkers for CRC patients.
lncRNA RP11-462C24.1 expression is decreased in CRC
cancer tissues. Additionally, the levels of RP11-462C24.1
are decreased in CRC patients with metastatic disease.
Multivariate analysis identified RP11-462C24.1 to be an
independent predictor of patient prognosis. Decreased
RP11-462C24.1 levels were also associated with
decreased disease-free survival. RP11-462C24.1 may be a
novel prognostic and diagnostic marker for CRC [56]. In
addition, prostate cancer non-coding RNA 1 (PRNCR1)
has also been investigated as a diagnostic marker for
CRC. Yang et al investigated the clinical significance and
biological function of PRNCR1 in CRC. In a cohort of
63 patients, PRNCR1 was significantly overexpressed in
CRC tissues compared to adjacent control tissues, and
PRNCR1 may be a sensitive diagnostic biomarker of CRC
[57].
Liu et al demonstrated NEAT1 (nuclear-enriched
abundant transcript 1) expression was increased in
colorectal cancer, and positively associated with tumor
differentiation, invasion, metastasis, and TNM stage.
Increased NEAT1 expression levels were correlated
with decreased patient survival. More importantly, Cox’s
proportional hazards analysis demonstrated increased
NEAT1 expression was an independent prognostic marker
of poor CRC patient outcome. Therefore, NEAT1 may be
a CRC prognostic indicator [58]. Wu et al analyzed the
expression of NEAT1 in blood, matched primary tumor
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Table 6: Clinical application
LncRNA

In colorectal cancer, its
expressions is:

Functions

Reference

DANCR

Upregulated

Serves as a potential prognosis
predictor for CRC patients,
associates with TNM stage,
histologic grade, and lymph node
metastasis, correlates with shorter
overall survival and disease-free
survival time.

[52]

FTX

Upregulated

Functions as an independent
prognostic factor for CRC patients,
associates with differentiation
grade, lymph vascular invasion,
and clinical stage, and predicts
poorer overall survival.

[53]

PCAT-1

Upregulated

Serves as an independent
prognostic factor for CRC outcome
and indicates poorer overall
survival.

[54, 55]

Downregulated

Serves as a prognosis indicator
for CRC patients, associates with
distant metastasis and poor diseasefree survival.

[56]

PRNCR1

Upregulated

Proved to be a sensitive diagnostic
biomarker of CRC.

[57]

NEAT1

Upregulated

Serves as a diagnostic and
prognostic biomarker of overall
survival in CRC, associates with
tumor differentiation, invasion,
metastasis and TNM stage, and
correlates with shorter disease-free
survival time and overall survival
time.

[58, 59]

HOTTIP

Upregulated

Predicts unfavorable prognosis for
CRC patients.

[37]

RP11-462C24.1

tissues, para-tumor tissues, metastatic tissues, and immune
cells from CRC patients and normal controls. Whole
blood NEAT1 expression was significantly increased
in colorectal cancer patients. Moreover, an elevated
expression of NEAT1 was also seen in neutrophils from
CRC patients [59]. In this sense, whole blood NEAT1
expression may be a novel diagnostic, prognostic, and
survival biomarker in colorectal cancer. Apart from
that, Ren et al characterized the role of a new lncRNA
HOTTIP (HOXA transcript at the distal tip) in CRC, and
demonstrated HOTTIP was increased in CRC tissues,
and positively correlated with clinical stage and distant
metastasis. Multivariate analysis suggests HOTTIP
overexpression to be an independent factor of poor CRC
prognosis [37]. These lncRNAs are potentially valuable
www.impactjournals.com/oncotarget

in clinical practice. However, there is still a long way for
them to go from bench to bedside.

CONCLUSION AND PERSPECTIVES
More than 1.2 million patients are diagnosed
annually with colorectal cancer, one of the most common
human malignancies. Comprehension of the underlying
molecular pathogenesis of the disease is urgently
needed. It is now recognized that mutations within the
noncoding genome are major determinants of human
diseases [60]. LncRNAs, which occupy a large size of
the noncoding genome, serve as important signals of
specific cellular states, and can be employed to identify
cellular pathologies such as cancer. In this review, we
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have carefully culled data supporting the use of lncRNAs
for diagnostic, prognostic, and potentially therapeutic
use for CRC patients. Currently, there remain significant
gaps in our understanding of lncRNA function in CRC.
The function of many lncRNAs in CRC development
and progression remain unknown. Efforts devoted to
elucidating the underlying molecular mechanisms of CRCspecific lncRNAs are warranted and necessary. Systematic
identification of potentially important lncRNAs central to
CRC pathophysiology is necessary to advance the medical
treatment of CRC for generations to come.
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